0001193125-20-165755.txt : 20200610 0001193125-20-165755.hdr.sgml : 20200610 20200610164540 ACCESSION NUMBER: 0001193125-20-165755 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200610 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200610 DATE AS OF CHANGE: 20200610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acadia Healthcare Company, Inc. CENTRAL INDEX KEY: 0001520697 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35331 FILM NUMBER: 20955213 BUSINESS ADDRESS: STREET 1: 6100 TOWER CIRCLE STREET 2: SUITE 1000 CITY: FRANKLIN STATE: TN ZIP: 37067 BUSINESS PHONE: 615-861-6000 MAIL ADDRESS: STREET 1: 6100 TOWER CIRCLE STREET 2: SUITE 1000 CITY: FRANKLIN STATE: TN ZIP: 37067 8-K 1 d942313d8k.htm 8-K 8-K
false 0001520697 0001520697 2020-06-10 2020-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 10, 2020

 

Acadia Healthcare Company, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

  

001-35331

  

45-2492228

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

6100 Tower Circle, Suite 1000

Franklin, Tennessee

  

37067

(Address of principal

executive offices)

  

(Zip Code)

(615)861-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.01 par value

  

ACHC

  

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 8.01 Other Events.

On June 10, 2020, Acadia Healthcare Company, Inc., a Delaware corporation (the “Company”), announced the pricing of its previously announced offering (the “Offering”) of $450 million aggregate principal amount of 5.500% senior notes due 2028 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.

The Company intends to use the net proceeds from the Offering, together with cash on hand, to redeem in full its outstanding 6.125% Senior Notes due 2021 (the “2021 Notes”) and 5.125% Senior Notes due 2022 (the “2022 Notes” and together with the 2021 Notes, the “Existing Notes”) and to pay related fees and expenses in connection therewith.    

On June 10, 2020, the Company issued a press release to announce the launch of the Offering. A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated by reference herein.

On June 10, 2020, the Company issued a press release to announce the pricing of the Notes. A copy of the press release is filed hereto as Exhibit 99.2 and is incorporated by reference herein.

On June 10, 2020, the Company issued (i) a notice of conditional full redemption providing for the redemption in full of the Company’s outstanding 2021 Notes at a redemption price equal to 100.000% of the principal amount of the 2021 Notes, plus accrued and unpaid interest, if any, to, but not including, July 10, 2020 (the “Redemption Date”), and (ii) a notice of conditional full redemption providing for the redemption in full of the Company’s outstanding 2022 Notes at a redemption price equal to 100.000% of the principal amount of the 2022 Notes, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. The redemption of the Existing Notes is conditioned upon the Company having received on or prior to the redemption date gross proceeds from the Offering of at least $450 million.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and the exhibits hereto contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. The forward-looking statements contained in this press release include statements related to the Offering, the use of proceeds therefrom and the redemption of the Existing Notes. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic; (ii) the Company’s ability to implement its business strategies in the U.S. and the U.K.; (iii) potential difficulties operating our business in light of political and economic instability in the U.K. and globally relating to the U.K.’s departure from the European Union; (iv) the impact of fluctuations in foreign exchange rates, including the devaluation of the British Pound Sterling (GBP) relative to the U.S. Dollar (USD); (v) the Company’s efforts to sell its U.K. operations may not result in any definitive transaction or enhance stockholder value, if the Company decides to pursue such a transaction in the future; (vi) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our acquisitions, joint ventures and de novo transactions; (vii) the Company’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (viii) potential reductions in payments received by the Company from government and commercial payors; (ix) the occurrence of patient incidents, governmental investigations and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (x) the Company’s significant debt and the restrictive covenants contained therein and otherwise in its agreements, which may restrict its business and financing activities; (xi) the risk that the Company may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (xii) potential operating difficulties, labor costs, client preferences, laws and regulations, interpretations of accounting principles or recent tax legislation, changes in competition and general economic or industry conditions

that may prevent the Company from realizing the expected benefits of its business strategies; and (xiii) the impact of governmental investigations, regulatory actions and whistleblower lawsuits. These factors and others are more fully described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and subsequent periodic reports and other filings with the SEC.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.

   

Description

         
 

99.1

   

Press Release of Acadia Healthcare Company, Inc., dated June 10, 2020

         
 

99.2

   

Press Release of Acadia Healthcare Company, Inc., dated June 10, 2020

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ACADIA HEALTHCARE COMPANY, INC.

             

Date: June 10, 2020

 

 

By:

 

/s/ Christopher L. Howard

 

 

 

Christopher L. Howard

 

 

 

Executive Vice President, Secretary and

General Counsel

EX-99.1 2 d942313dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Contact:    

Gretchen Hommrich

Director, Investor Relations

(615) 861-6000

ACADIA HEALTHCARE ANNOUNCES LAUNCH

OF $450 MILLION SENIOR NOTES OFFERING

FRANKLIN, Tenn. (June 10, 2020) – Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today that it has launched a private offering (the “Offering”) of senior notes due 2028 (the “Notes”), subject to customary and market conditions.

The Company intends to use the net proceeds from the Offering, together with cash on hand, to redeem in full its outstanding 6.125% Senior Notes due 2021 (the “2021 Notes”) and 5.125% Senior Notes due 2022 (the “2022 Notes” and together with the 2021 Notes, the “Existing Notes”) and to pay related fees and expenses in connection therewith.

The Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the Notes are being offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act.

A confidential offering memorandum for the Offering of the Notes, dated as of today, is being made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum. This press release does not constitute a notice to redeem the Existing Notes.

About Acadia

Acadia is a leading provider of behavioral healthcare services. As of March 31, 2020, Acadia operated a network of 588 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the United Kingdom and Puerto Rico. Acadia provides behavioral health and addiction treatment services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Acadia also offers anyone in need of mental health or addiction services a free, national behavioral health crisis line at 1-833-TREATBH (873-2824).

 

-MORE-

ACHC Announces Launch of $450 Million Senior Notes Offering

Page 2

June 10, 2020

 

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. The forward-looking statements contained in this press release include statements related to the Offering and the use of proceeds therefrom. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic; (ii) Acadia’s ability to implement its business strategies in the U.S. and the U.K.; (iii) potential difficulties operating our business in light of political and economic instability in the U.K. and globally relating to the U.K.’s departure from the European Union; (iv) the impact of fluctuations in foreign exchange rates, including the devaluation of the British Pound Sterling (GBP) relative to the U.S. Dollar (USD); (v) Acadia’s efforts to sell its U.K. operations may not result in any definitive transaction or enhance stockholder value, if Acadia decides to pursue such a transaction in the future; (vi) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our acquisitions, joint ventures and de novo transactions; (vii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (viii) potential reductions in payments received by Acadia from government and commercial payors; (ix) the occurrence of patient incidents, governmental investigations and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (x) Acadia’s significant debt and the restrictive covenants contained therein and otherwise in its agreements, which may restrict its business and financing activities; (xi) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (xii) potential operating difficulties, labor costs, client preferences, laws and regulations, interpretations of accounting principles or recent tax legislation, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies; and (xiii) the impact of governmental investigations, regulatory actions and whistleblower lawsuits. These factors and others are more fully described in Acadia’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and subsequent periodic reports and other filings with the SEC.

 

-END-

EX-99.2 3 d942313dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

Contact:

Gretchen Hommrich

Director, Investor Relations

(615) 861-6000

ACADIA HEALTHCARE ANNOUNCES PRICING OF $450 MILLION SENIOR NOTES DUE

2028 AND INTENTION TO REDEEM ITS 2021 NOTES AND 2022 NOTES

FRANKLIN, Tenn. (June 10, 2020) – Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today the pricing of its previously announced private offering (the “Offering”) of $450 million in aggregate principal amount of its 5.500% senior notes due 2028 (the “Notes”). The Offering is expected to close on June 24, 2020. The closing of the Offering is subject to the satisfaction of customary and market conditions.

The Company intends to use the net proceeds from the Offering, together with cash on hand, to redeem in full its outstanding 6.125% Senior Notes due 2021 (the “2021 Notes”) and 5.125% Senior Notes due 2022 (the “2022 Notes” and together with the 2021 Notes, the “Existing Notes”) and to pay related fees and expenses in connection therewith.

The Notes will bear interest at the rate of 5.500% per year. Interest on the Notes will be payable semi-annually in arrears on January 1 and July 1 of each year, commencing January 1, 2021. The Notes will mature on July 1, 2028. The Notes were offered at a price of 100% of the principal amount.

On June 10, 2020, the Company issued (i) a notice of conditional full redemption providing for the redemption in full of the Company’s outstanding 2021 Notes at a redemption price equal to 100.000% of the principal amount of the 2021 Notes, plus accrued and unpaid interest, if any, to, but not including, July 10, 2020 (the “Redemption Date”), and (ii) a notice of conditional full redemption providing for the redemption in full of the Company’s outstanding 2022 Notes at a redemption price equal to 100.000% of the principal amount of the 2022 Notes, plus accrued and unpaid interest, if any, to, but not including, the Redemption Date. The redemption of the Existing Notes is conditioned upon the Company having received on or prior to the redemption date gross proceeds from the Offering of at least $450 million.

The Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the Notes were offered only to persons reasonably believed to be “qualified institutional buyers,” as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-“U.S. persons” in accordance with Regulation S under the Securities Act.

 

-MORE-

ACHC Announces Pricing Of $450 Million Senior Notes Due 2028 And Intention To Redeem Its 2021 Notes And 2022 Notes

Page 2

June 10, 2020

 

A confidential offering memorandum for the Offering of the Notes has been made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum. This press release does not constitute a notice to redeem the Existing Notes.

About Acadia

Acadia is a leading provider of behavioral healthcare services. As of March 31, 2020, Acadia operated a network of 588 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the United Kingdom, and Puerto Rico. Acadia provides behavioral health and addiction treatment services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics. Acadia also offers anyone in need of mental health or addiction services a free, national behavioral health crisis line at 1-833-TREATBH (873-2824).

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. The forward-looking statements contained in this press release include statements related to the Offering, the use of proceeds therefrom and the redemption of the Existing Notes. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic; (ii) Acadia’s ability to implement its business strategies in the U.S. and the U.K.; (iii) potential difficulties operating our business in light of political and economic instability in the U.K. and globally relating to the U.K.’s departure from the European Union; (iv) the impact of fluctuations in foreign exchange rates, including the devaluation of the British Pound Sterling (GBP) relative to the U.S. Dollar (USD); (v) Acadia’s efforts to sell its U.K. operations may not result in any definitive transaction or enhance stockholder value, if Acadia decides to pursue such a transaction in the future; (vi) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our acquisitions, joint ventures and de novo transactions; (vii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (viii) potential reductions in payments received by Acadia from government and commercial payors; (ix) the occurrence of patient incidents, governmental investigations and adverse regulatory actions, which could adversely affect the price of our

ACHC Announces Pricing Of $450 Million Senior Notes Due 2028 And Intention To Redeem Its 2021 Notes And 2022 Notes

Page 3

June 10, 2020

 

common stock and result in substantial payments and incremental regulatory burdens; (x) Acadia’s significant debt and the restrictive covenants contained therein and otherwise in its agreements, which may restrict its business and financing activities; (xi) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (xii) potential operating difficulties, labor costs, client preferences, laws and regulations, interpretations of accounting principles or recent tax legislation, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies; and (xiii) the impact of governmental investigations, regulatory actions and whistleblower lawsuits. These factors and others are more fully described in Acadia’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 and subsequent periodic reports and other filings with the SEC.

-END-

EX-101.SCH 4 achc-20200610.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 achc-20200610_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 achc-20200610_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g942313graphics.jpg GRAPHIC begin 644 g942313graphics.jpg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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Jun. 10, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001520697
Document Type 8-K
Document Period End Date Jun. 10, 2020
Entity Registrant Name Acadia Healthcare Company, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-35331
Entity Tax Identification Number 45-2492228
Entity Address, Address Line One 6100 Tower Circle
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Franklin
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37067
City Area Code (615)
Local Phone Number 861-6000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value
Trading Symbol ACHC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 d942313d8k_htm.xml IDEA: XBRL DOCUMENT 0001520697 2020-06-10 2020-06-10 false 0001520697 8-K 2020-06-10 Acadia Healthcare Company, Inc. DE 001-35331 45-2492228 6100 Tower Circle Suite 1000 Franklin TN 37067 (615) 861-6000 false false false false Common Stock, $0.01 par value ACHC NASDAQ false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d942313d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d942313d8k.htm" ] }, "labelLink": { "local": [ "achc-20200610_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "achc-20200610_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "achc-20200610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "achc", "nsuri": "http://www.acadiahealthcare.com/20200610", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d942313d8k.htm", "contextRef": "duration_2020-06-10_to_2020-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d942313d8k.htm", "contextRef": "duration_2020-06-10_to_2020-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.acadiahealthcare.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d942313d8k.htm achc-20200610.xsd achc-20200610_lab.xml achc-20200610_pre.xml d942313dex991.htm d942313dex992.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 15 0001193125-20-165755-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-165755-xbrl.zip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end EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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